Hendricks, Abby K.

ABSTRACT Pharmacy preceptors are central to experiential learning, yet there is a lack of guidance on how to integrate generative artificial intelligence (GenAI) into precepting. This paper serves as a practical “how‐to” resource, offering actionable strategies and examples to help preceptors implement GenAI into clinical education. Based on examples from multiple institutions and the best available literature in pharmacy practice and education, we outline step‐by‐step approaches for designing learning activities, adapting assessment methods, and modeling effective artificial intelligence (AI) use, with a focus on optimizing learner engagement, personalizing instruction, cultivating critical thinking, and building AI literacy. Implementation guidance includes creating transparent AI use policies, safeguarding confidentiality, preventing deskilling, and embedding GenAI into feedback and evaluation processes. By incorporating these recommendations, preceptors can augment experiential education into a setting where learners can explore GenAI applications and build the judgment required to use AI responsibly in pharmacy practice.

AbstractBackgroundPolypharmacy in older adults leads to increased risks of side effects and drug‐drug interactions, affecting their health outcomes and quality of life. Deprescribing, the act of simplifying medication regimens, is challenging due to the lack of consensus guidelines.HypothesisTo offer some guidance on managing medication regimens for older cardiovascular patients.MethodsWe reviewed the most recent pertinent guidelines and literature.ResultsThis review provides practical considerations for appropriate prescribing in the older population with cardiovascular disease in order to strike a balance between unnecessary or harmful medications and therapies with proven long‐term benefits.ConclusionOn‐going dialogue between healthcare providers and patients allows close monitoring of medication effectiveness and prevention of side effects. Medication regimens require individualization, as patients' goals of care change with advancing age.

Background: Use of an anticoagulant after transcatheter aortic valve replacement (TAVR) has been increasing in practice after noted leaflet thrombosis on dual antiplatelet therapy. As the use of anticoagulation increases so does the number of poor warfarin candidates or warfarin intolerant patients. While direct oral anticoagulant (DOAC) use is increasing for other indications, there is a paucity of data for use after TAVR. The objective of this case series is to add to the available evidence for patients who may require a DOAC after TAVR. Methods: A single-center, retrospective observational case series was conducted including adults 18 years of age and older who received a DOAC after TAVR between November 2008 and June 2018 at Mayo Clinic Hospital—Rochester. All patients were identified as part of the Society of Thoracic Surgeons database. Results: Twenty-one patients were identified as having received a DOAC after TAVR. Median age was 83.5 years (interquartile range 77–87), with 71% males. Within this cohort, 20 patients (95.2%) had an alternative indication for anticoagulation of either atrial fibrillation or atrial flutter. Apixaban was prescribed in 66.7% of patients, followed by rivaroxaban (14.3%), dabigatran (9.5%), and edoxaban (4.8%). No thromboembolic events were reported. Three patients experienced a bleeding event, of which only 2 occurred in the 3 months immediately after TAVR. Conclusions: DOAC therapy after TAVR was generally safe and well tolerated. Taken in context of other retrospective studies, these data suggest that the presence of valvular heart disease, specifically TAVR in this case, should not preclude the use of DOACs.